View in EDS

Psychometric Properties of the Scale for Subjective Somatic and Cognitive Complaints of Psychotropic Medication Adult‐Aged‐Spectrum (SCOPA)

Saved in:
Bibliographic Details
Title: Psychometric Properties of the Scale for Subjective Somatic and Cognitive Complaints of Psychotropic Medication Adult‐Aged‐Spectrum (SCOPA)
Authors: Levi J. M. Schuurman, Sjacko Sobczak, Julie E. M. Schulkens, Benno P. F. Balter, Sebastiaan P. J. van Alphen
Source: Hum Psychopharmacol
Publisher Information: Wiley, 2025.
Publication Year: 2025
Subject Terms: Adult, Male, Psychometrics, Adolescent, construct validity, Reproducibility of Results, Middle Aged, Psychotropic Drugs/adverse effects, Mental Disorders/drug therapy, pharmacotherapy, side effects, Young Adult, psychotropic medication, Surveys and Questionnaires, internal consistency, 80 and over, Cognition/drug effects, Humans, Female, older adults, Aged, Netherlands, Research Article
Description: ObjectivePatient‐reported side‐effect questionnaires contribute to balanced decisions regarding treatment strategy among patients with mental health disorders. However, current side‐effect questionnaires are less suitable for older adults because they often lack age‐specific side effects. Therefore, the Scale for Subjective Somatic and Cognitive Complaints of Psychotropic Medication Adult‐Aged‐Spectrum (SCOPA) was developed to quantify psychotropic side effects across the full adult age spectrum. The aim of this study was to develop and evaluate the reliability and validity of the SCOPA.ProceduresPsychometric properties of the SCOPA were assessed in a Dutch patient population (n = 205, age 18–86 years) and a general population (n = 281, age 18–87 years). Reliability of the subscales was measured through average inter‐item correlation and Cronbach's alphas. Construct validity was analysed by exploratory factor analysis.ResultsAverage inter‐item correlation and Cronbach's alphas of the subscales of the SCOPA were moderate to good. Exploratory factor analyses supported a two‐factor solution, labelled as complaints in somatic and cognitive domains.ConclusionsThis study showed that the SCOPA has promising psychometric qualities and practical capability to evaluate the side‐effect burden of treatment with psychotropic medication across the adult‐aged‐spectrum. However, more research is needed to cross‐validate these results in the field's pursuit of increased patient safety.
Document Type: Article
Other literature type
Language: English
ISSN: 1099-1077
0885-6222
DOI: 10.1002/hup.70009
Access URL: https://cris.maastrichtuniversity.nl/en/publications/abb95363-fd0b-4f70-8bf3-1936ba34d524
https://doi.org/10.1002/hup.70009
Rights: CC BY
Accession Number: edsair.doi.dedup.....5b5e12aab7697ec56e9946926a288e5d
Database: OpenAIRE
Description
Abstract:ObjectivePatient‐reported side‐effect questionnaires contribute to balanced decisions regarding treatment strategy among patients with mental health disorders. However, current side‐effect questionnaires are less suitable for older adults because they often lack age‐specific side effects. Therefore, the Scale for Subjective Somatic and Cognitive Complaints of Psychotropic Medication Adult‐Aged‐Spectrum (SCOPA) was developed to quantify psychotropic side effects across the full adult age spectrum. The aim of this study was to develop and evaluate the reliability and validity of the SCOPA.ProceduresPsychometric properties of the SCOPA were assessed in a Dutch patient population (n = 205, age 18–86 years) and a general population (n = 281, age 18–87 years). Reliability of the subscales was measured through average inter‐item correlation and Cronbach's alphas. Construct validity was analysed by exploratory factor analysis.ResultsAverage inter‐item correlation and Cronbach's alphas of the subscales of the SCOPA were moderate to good. Exploratory factor analyses supported a two‐factor solution, labelled as complaints in somatic and cognitive domains.ConclusionsThis study showed that the SCOPA has promising psychometric qualities and practical capability to evaluate the side‐effect burden of treatment with psychotropic medication across the adult‐aged‐spectrum. However, more research is needed to cross‐validate these results in the field's pursuit of increased patient safety.
ISSN:10991077
08856222
DOI:10.1002/hup.70009